Identifying HIV Drug Resistance Mutations in Mozambique

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This observational study aims to investigate whether patients with uncontrolled HIV infection, despite being on antiretroviral therapy, develop mutations that confer resistance to these treatments. Participants will provide a blood sample for analysis of HIV mutations, alongside demographic and clinical data. The study will focus on patients who have been on the first-line treatment regimen for at least six months and have a viral load above 200 copies/ml. The findings could help understand the relationship between treatment adherence and the emergence of drug resistance.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Patients able to understand and sign the informed consent form.
* Documented HIV-1 infection.
* Under the first line TLD for at least 6 months.
* At least 3 months follow-up with CV \>200c/ml.

Exclusion Criteria:

* Patients \<18 years of age.
* Under the first line regime other than TLD.
* Patients with active neoplastic processes.
* Patients with active opportunistic diseases.
* Patients unable to give informed consent.

Where it's running

• Hospital Carmelo
  Chokwé, Mozambique Recruiting

Study contacts

• Study coordinator: Daniel Podzamczer, PhD
• Email: dpodzamczer@gmail.com
• Phone: 0034675335888

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Supportive housing program for people with HIV

  This study is testing a supportive housing program for people with HIV to see if it helps them manage their health better and stay in stable housing.

  Recruiting University of Pennsylvania · Philadelphia, Pennsylvania and 1 other locations · NCT06829394

• Project SHIELD 2.0: Police Education to Support Public Health in Kentucky

  Aimed at police in Kentucky, this program tests whether SHIELD training given to officers, with health workers helping deliver it, can reduce drug-related arrests and steer people who use drugs toward MOUD and other health services.

  Recruiting Johns Hopkins Bloomberg School of Public Health · Lexington, Kentucky · NCT07804121

• New ways to diagnose lymphoma and multicentric Castleman disease in people living with HIV

  This study tests a quick, point-of-care nucleic acid test to help diagnose lymphoma and multicentric Castleman disease in people living with HIV in sub-Saharan Africa.

  Recruiting Indiana University · Lilongwe · NCT07793006

• Bridge to Belonging: A Peer‑Led Program to Reduce Loneliness and Depression in older gay and bisexual men with HIV

  This program tests a peer-delivered, manualized approach to help men aged 50+ with HIV connect to LGBTQ+-affirming elder services to see if it reduces loneliness and depressive symptoms.

  Recruiting Fenway Community Health · Boston, Massachusetts · NCT07762066

• HIV vaccine test in healthy adults using CH505 nanoparticles and mRNA boosters

  This early-stage study will test the safety and immune responses of CH505 vaccine regimens in healthy adults to see if they can trigger HIV-specific immune protection.

  Recruiting at 2 sites Phase 1 National Institute of Allergy and Infectious Diseases (NIAID) · San Francisco, California and 7 other locations · NCT07757802

• Stigma-reducing program to help women who use drugs stay in HIV care

  This test checks whether a stigma-reduction program helps women living with HIV who use drugs stay engaged in HIV care in Ukraine.

  Recruiting Johns Hopkins Bloomberg School of Public Health · Kyiv, Kyiv Oblast · NCT07751978

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.